Abstract:Epithelial ovarian cancer (EOC), a leading cause of gynecological cancer-related morbidity and mortality and the most common type of ovarian cancer (OC), is widely characterized by alterations in the Epidermal Growth Factor (EGF) signaling pathways. The phenomenon of metastasis is largely held accountable for the majority of EOC-associated deaths. Existing literature reports substantiate evidence on the indispensable role of metabolic reprogramming, particularly the phenomenon of the 'Warburg effect' or aerobic glycolysis in priming the cancer cells towards Epithelial to Mesenchymal transition (EMT), subsequently facilitating EMT. Considering the diverse roles of growth factor signaling across different stages of oncogenesis, our prime emphasis was laid on unraveling mechanistic details of EGF-induced 'Warburg effect' and resultant metastasis in EOC cells. Our study puts forth Ets1, an established oncoprotein and key player in OC progression, as the prime metabolic sensor to EGF-induced cues from the tumor microenvironment (TME). EGF treatment has been found to induce Ets1 expression in OC cells predominantly through the Extracellular Signal-Regulated Kinase1/2 (ERK1/2) pathway activation. This subsequently results in pronounced glycolysis, characterized by an enhanced lactate production through transcriptional up-regulation of key determinant genes of the central carbon metabolism namely, hexokinase 2 (HK2) and monocarboxylate transporter 4 (MCT4). Furthermore, this study reports an unforeseen combinatorial blockage of HK2 and MCT4 as an effective approach to mitigate cellular metastasis in OC. Collectively, our work proposes a novel mechanistic insight into EGF-induced glycolytic bias in OC cells and also sheds light on an effective therapeutic intervention approach exploiting these insights.

Tumor metabolism rewiring in epithelial ovarian cancer

Exploring Metabolic Approaches for Epithelial Ovarian Cancer Therapy

Metabolic reprogramming in epithelial ovarian cancer.

Metabolic adaptation in epithelial ovarian cancer metastasis

Metabolic Reprogramming and Interventions in Endometrial Carcinoma.

One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer

Metabolic Cross-Talk Between Ovarian Cancer and the Tumor Microenvironment-Providing Potential Targets for Cancer Therapy.

Metabolic cross-talk between ovarian cancer and the tumor microenvironment-providing potential targets for cancer therapy

Metabolic Phenotyping for Monitoring Ovarian Cancer Patients

ETS1 drives EGF-induced glycolytic shift and metastasis of epithelial ovarian cancer cells

Metabolic and senescence characteristics associated with the immune microenvironment in ovarian cancer

Metabolic Reprogramming in Tumor-Associated Macrophages in the Ovarian Tumor Microenvironment

Metabolic reprogramming of the tumor immune microenvironment in ovarian cancer: A novel orientation for immunotherapy

Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance

Metabolic Interplay in the Tumor Microenvironment: Implications for Immune Function and Anticancer Response

Mapping the expression and functional landscape of key enzymes in glucose metabolism within human gynecological tumors

Glucose metabolism reprogramming in gynecologic malignant tumors

Metabolic reprogramming of three major nutrients in platinum-resistant ovarian cancer

Interplay between altered metabolism and DNA damage and repair in ovarian cancer

Altered metabolism in cancer: insights into energy pathways and therapeutic targets

Tumor Energy Metabolism: Implications for Therapeutic Targets